SeekingAlpha · Aug 10, 2026
Santen Pharmaceutical Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation
2026-08-10. The following slide deck was published by Santen Pharmaceutical Co., Ltd.
SN
OTC · SNPHY
Santen Pharmaceutical Co., Ltd.
Healthcare · Drug Manufacturers - General
$11.27
Up+$0.35 (+3.21%)
Updated Sep 13, 2026, 4:48 PM
SID Score
6.1/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 3.5B
- P/E ratio
- 16.37
- Dividend yield
- 2.29%
- 52-week range
- — – —
- Volume
- 300
- Avg. volume
- 12.41K
Price performance
SNPHY price history
1M range · 0 trading sessions · Daily adjusted prices
SNPHY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest SNPHY news
The latest Smart Investors Daily articles mentioning SNPHY.
Stock researchCompany · Overview
SNPHY research
Overview
Company profile and research snapshot.
Company profile
SANTEN PHARM CO UNSP/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $13.61
- Implied upside
- —
- Analysts
- 13
News briefing
No generated briefing is available yet.
Benzinga · Aug 6, 2026
Santen Pharmaceutical Q1 EPS $0.11 Misses $0.12 Estimate, Sales $431.325M Beat $418.770M Estimate
Santen Pharmaceutical (OTC:SNPHY) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.12 by 8.33 percent. This is a 8.33 percent decrease over earnings of $0.12 per share
Yahoo · Jan 8, 2026
RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%
RVL Pharmaceuticals, Inc. and its affiliates (together, "RVL") announces Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% (generic name: oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids).
GlobeNewswire Inc. · Apr 8, 2025
Ophthalmology Market Report 2025 | Industry to Reach US$93.7 Billion by 2030 | Emerging Research Activities of Ophthalmology Treatments and Availability of Grants Present Business Opportunities
The global ophthalmology market is expected to grow at a CAGR of 6.62%, reaching $93.69 billion by 2030, driven by advancements in technology, personalized medicine, and improved healthcare access.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
